Component
Valeryl (pentanoyl) salicylate
Valeryl (pentanoyl) salicylate. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Valeryl (pentanoyl) salicylate was the only compound of eight acyl salicylates to show isozyme selectivity and inhibited human cyclooxygenase-1 much more effectively than cyclooxygenase-2 in a time-dependent manner, inhibited ovine cyclooxygenase-1 but did not inhibit the S530A mutant of ovine cyclooxygenase-1 which is also refractory to acetylsalicylate, so valeryl salicylate acylates the active site serine.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/aspirin-research/7872783.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b", "start_char": 0, "end_char": 1756, "text_sha256": "f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b"}
- experimental_model
- Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control
- exposure
- Valeryl salicylate and related esters compared with acetylsalicylate
- limitations
- Uses the acetylation chemistry as a design principle and confirms the serine requirement with a mutant. Recombinant enzyme and a murine fibroblast line, not human tissue.
- nutrient_topic
- Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. · Aspirin / acetylsalicylic acid
- organism
- Human and sheep enzyme
- plain_language
- Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme.
- primary_references
- [asa-p7872783] Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. (1995). https://pubmed.ncbi.nlm.nih.gov/7872783/ DOI: 10.1006/abbi.1995.1130
- tissue_or_cell_type
- Recombinant cyclooxygenase
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control · source_derived_draft · unverified_draft
### asa-bigger-acyl-group-selective Valeryl (pentanoyl) salicylate was the only compound of eight acyl salicylates to show isozyme selectivity and inhibited human cyclooxygenase-1 much more effectively than cyclooxygenase-2 in a time-dependent manner, inhibited ovine cyclooxygenase-1 but did not inhibit the S530A mutant of ovine cyclooxygenase-1 which is also refractory to acetylsalicylate, so valeryl salicylate acylates the active site serine. Condition category: normal nutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes. plain_language: Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme. organism: Human and sheep enzyme tissue_or_cell_type: Recombinant cyclooxygenase experimental_model: Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control limitations: Uses the acetylation chemistry as a design principle and confirms the serine requirement with a mutant. Recombinant enzyme and a murine fibroblast line, not human tissue. exposure: Valeryl salicylate and related esters compared with acetylsalicylate evidence_span: {"source_cache": "artifacts/aspirin-research/7872783.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b", "start_char": 0, "end_char": 1756, "text_sha256": "f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b"} [asa-p7872783] Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. (1995). https://pubmed.ncbi.nlm.nih.gov/7872783/ DOI: 10.1006/abbi.1995.1130
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.